Trial · NCT05572957
LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB
NCT05572957, Not applicable, Active not recruiting, The First Affiliated Hospital with Nanjing Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB. Trials, record NCT05572957. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05572957
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB
- NCT number
- NCT05572957
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 50 participants, estimated
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Conditions
- Non-ischemic Cardiomyopathy, Heart Failure, Left Bundle-Branch Block
- Interventions
- Guideline-Directed Medical Therapy(GDMT), left bundle branch pacing combined with Guideline-Directed Medical Therapy(LBBP+GDMT)
- First posted
- 2022-10-10
- Last updated
- 2026-05-14
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of patients requiring ICD implantation for prevention of sudden cardiac death(SCD) | 6-month follow-up | After treatment with two strategies(GDMT, LBBP+GDMT), the percentages of LVEF still ≤35% and/or ventricular arrhythmia events was assessed in both groups. That is, the percentage of patients who are eligible for primary/secondary prevention ICD implantation. |
| Secondary | Health economics | 3-month, 6-month, 12-month, and 18-month follow-up | The cost of the two treatment strategies were evaluated comprehensively, including each inpatient, outpatient and unplanned follow-up |
| Secondary | Changes in LVEF | Baseline; 3-month, 6-month, 12-month, and 18-month follow-up | LVEF is assessed by echocardiography (Simpson's rule) and compared between the baseline and follow-up. |
| Secondary | Changes in LVESV | Baseline; 3-month, 6-month, 12-month, and 18-month follow-up | LVESV is assessed by echocardiography (Simpson's rule) and compared between the baseline and follow-up. |
| Secondary | Changes in LVEDV | Baseline; 3-month, 6-month, 12-month, and 18-month follow-up | LVEDV is assessed by echocardiography (Simpson's rule) and compared between the baseline and follow-up. |
| Secondary | Changes in concentration of NT-proBNP in blood between baseline and follow-up | Baseline; 3-month, 6-month, 12-month, and 18-month follow-up | Blood test is performed at each time frame to determine the concentration of NT-proBNP(unit: pg/mL) |
| Secondary | Changes in New York Heart Association Heart Function Classification between baseline and follow-up | Baseline; 3-month, 6-month, 12-month, and 18-month follow-up | The higher the classification, the more severe the heart failure symptoms(four levels: I, II, III and IV) |
| Secondary | Change in Quality Of Life Questionnaire score between baseline and follow-up | Baseline; 3-month, 6-month, 12-month, and 18-month follow-up | Reflect the effect of heart failure on quality of life, and higher scores represent a worse outcome |
| Secondary | Incidence of clinical adverse events | Baseline; 3-month, 6-month, 12-month, and 18-month follow-up | Including date and number of all-cause mortality, heart failure hospitalization, cardiovascular hospitalization and malignant ventricular arrhythmia |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05572957
GET https://conductscience.org/api/trials/v1/NCT05572957/registered